Skip to main content
. 2015 Mar 24;50(1):7–18. doi: 10.5045/br.2015.50.1.7

Table 2. Summary of key clinical data from 2 large (>100 patients) multicenter, noncomparative studies (Korea and China) in Asian patients receiving lenalidomide/dexamethasone for relapsed or refractory multiple myeloma [17, 18].

graphic file with name br-50-7-i002.jpg

a)Primary efficacy population (safety population: N=199).

Abbreviations: BOR, bortezomib; CI, confidence interval; NR, not reported; OS, overall survival; PFS, progression-free survival; PR, partial response; THD, thalidomide; TTP, time to progression.